Epstein, M. Anthony (2005). "1. The origins of EBV research: discovery and characterization of the virus". En Robertson, Earl S. Epstein–Barr Virus. Trowbridge: Cromwell Press. pp. 1–14. ISBN1-904455-03-4. Consultado o September 18, 2010.
Maeda E, Akahane M, Kiryu S; et al. (January 2009). "Spectrum of Epstein–Barr virus-related diseases: a pictorial review". Jpn J Radiol27 (1): 4–19. PMID19373526. doi:10.1007/s11604-008-0291-2.
Toussirot E, Roudier J (October 2008). "Epstein–Barr virus in autoimmune diseases". Best Practice & Research. Clinical Rheumatology22 (5): 883–96. PMID19028369. doi:10.1016/j.berh.2008.09.007.
Amon, Wolfgang; Farrell (November 2004). "Reactivation of Epstein–Barr virus from latency". Reviews in Medical Virology15 (3): 149–56. PMID15546128. doi:10.1002/rmv.456.
Pannone, Giuseppe; Zamparese, Rosanna; Pace, Mirella; Pedicillo, Maria; Cagiano, Simona; Somma, Pasquale; Errico, Maria; Donofrio, Vittoria; Franco, Renato; De Chiara, Annarosaria; Aquino, Gabriella; Bucci, Paolo; Bucci, Eduardo; Santoro, Angela; Bufo, Pantaleo (2014). "The role of EBV in the pathogenesis of Burkitt’s Lymphoma: an Italian hospital based survey". Infectious Agents and Cancer9 (1): 34. ISSN1750-9378. doi:10.1186/1750-9378-9-34.
Henle W, Henle G (1980). "Epidemiologic aspects of Epstein–Barr virus (EBV)-associated diseases". Annals of the New York Academy of Sciences354: 326–31. PMID6261650. doi:10.1111/j.1749-6632.1980.tb27975.x.
Calderwood MA, Venkatesan K, Xing L, Chase MR, Vazquez A, Holthaus AM, Ewence AE, Li N, Hirozane-Kishikawa T, Hill DE, Vidal M, Kieff E, Johannsen E (May 2007). "Epstein–Barr virus and virus human protein interaction maps". Proceedings of the National Academy of Sciences of the United States of America104 (18): 7606–11. PMC1863443. PMID17446270. doi:10.1073/pnas.0702332104. A nomenclatura que se usará aquí é a de Kieff, pero outros laboratorios usan nomenclaturas diferentes.
Yates JL, Warren N, Sugden B (1985). "Stable replication of plasmids derived from Epstein–Barr virus in various mammalian cells". Nature313 (6005): 812–5. PMID2983224. doi:10.1038/313812a0.
Buisson M, Géoui T, Flot D, Tarbouriech N, Ressing ME, Wiertz EJ, Burmeister WP (2009). "A bridge crosses the active-site canyon of the Epstein–Barr virus nuclease with DNase and RNase activities". J Mol. Biol.319 (4): 717–28. PMID19538972. doi:10.1016/j.jmb.2009.06.034.
Buisson, M.; Géoui, T.; Flot, D.; Tarbouriech, N.; Ressing, M. E.; Wiertz, E. J.; Burmeister, W. P. (2009). "A Bridge Crosses the Active-Site Canyon of the Epstein–Barr Virus Nuclease with DNase and RNase Activities". Journal of Molecular Biology391 (4): 717–728. PMID19538972. doi:10.1016/j.jmb.2009.06.034.
Delecluse HJ, Feederle R, Behrends U, Mautner J (December 2008). "Contribution of viral recombinants to the study of the immune response against the Epstein–Barr virus". Seminars in Cancer Biology18 (6): 409–15. PMID18938248. doi:10.1016/j.semcancer.2008.09.001.
Maeda E, Akahane M, Kiryu S; et al. (January 2009). "Spectrum of Epstein–Barr virus-related diseases: a pictorial review". Jpn J Radiol27 (1): 4–19. PMID19373526. doi:10.1007/s11604-008-0291-2.
Amon, Wolfgang; Farrell (November 2004). "Reactivation of Epstein–Barr virus from latency". Reviews in Medical Virology15 (3): 149–56. PMID15546128. doi:10.1002/rmv.456.
Henle W, Henle G (1980). "Epidemiologic aspects of Epstein–Barr virus (EBV)-associated diseases". Annals of the New York Academy of Sciences354: 326–31. PMID6261650. doi:10.1111/j.1749-6632.1980.tb27975.x.
Calderwood MA, Venkatesan K, Xing L, Chase MR, Vazquez A, Holthaus AM, Ewence AE, Li N, Hirozane-Kishikawa T, Hill DE, Vidal M, Kieff E, Johannsen E (May 2007). "Epstein–Barr virus and virus human protein interaction maps". Proceedings of the National Academy of Sciences of the United States of America104 (18): 7606–11. PMC1863443. PMID17446270. doi:10.1073/pnas.0702332104. A nomenclatura que se usará aquí é a de Kieff, pero outros laboratorios usan nomenclaturas diferentes.
Westphal EM, Blackstock W, Feng W, Israel B, Kenney SC. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res. 2000 Oct 15;60(20):5781-8. PMID 11059774
Yates JL, Warren N, Sugden B (1985). "Stable replication of plasmids derived from Epstein–Barr virus in various mammalian cells". Nature313 (6005): 812–5. PMID2983224. doi:10.1038/313812a0.
Buisson M, Géoui T, Flot D, Tarbouriech N, Ressing ME, Wiertz EJ, Burmeister WP (2009). "A bridge crosses the active-site canyon of the Epstein–Barr virus nuclease with DNase and RNase activities". J Mol. Biol.319 (4): 717–28. PMID19538972. doi:10.1016/j.jmb.2009.06.034.
Buisson, M.; Géoui, T.; Flot, D.; Tarbouriech, N.; Ressing, M. E.; Wiertz, E. J.; Burmeister, W. P. (2009). "A Bridge Crosses the Active-Site Canyon of the Epstein–Barr Virus Nuclease with DNase and RNase Activities". Journal of Molecular Biology391 (4): 717–728. PMID19538972. doi:10.1016/j.jmb.2009.06.034.
Delecluse HJ, Feederle R, Behrends U, Mautner J (December 2008). "Contribution of viral recombinants to the study of the immune response against the Epstein–Barr virus". Seminars in Cancer Biology18 (6): 409–15. PMID18938248. doi:10.1016/j.semcancer.2008.09.001.
Xiangrong Gaoa, Kazufumi Ikutaa, Masako Tajimab, Takeshi Sairenjia. 12-O-Tetradecanoylphorbol-13-acetate Induces Epstein–Barr Virus Reactivation via NF-κB and AP-1 as Regulated by Protein Kinase C and Mitogen-Activated Protein Kinase. Virology. Volume 286, Issue 1, 20 July 2001, Pages 91–99. doi 10.1006/viro.2001.0965. [1]
Pannone, Giuseppe; Zamparese, Rosanna; Pace, Mirella; Pedicillo, Maria; Cagiano, Simona; Somma, Pasquale; Errico, Maria; Donofrio, Vittoria; Franco, Renato; De Chiara, Annarosaria; Aquino, Gabriella; Bucci, Paolo; Bucci, Eduardo; Santoro, Angela; Bufo, Pantaleo (2014). "The role of EBV in the pathogenesis of Burkitt’s Lymphoma: an Italian hospital based survey". Infectious Agents and Cancer9 (1): 34. ISSN1750-9378. doi:10.1186/1750-9378-9-34.
